We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Clinical outcome for EML4-ALK-positive patients with advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy.
- Authors
Takeda, M; Okamoto, I; Sakai, K; Kawakami, H; Nishio, K; Nakagawa, K
- Abstract
The EML4-ALK fusion oncogene represents a recently identified molecular target in a subset of patients with non-small-cell lung cancer (NSCLC). Limited data have been available, however, on the outcome of first-line platinum-based chemotherapy in patients with EML4-ALK-positive advanced NSCLC who have not been treated with an ALK kinase inhibitor.
- Publication
Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Vol 23, Issue 11, p2931
- ISSN
1569-8041
- Publication type
Journal Article
- DOI
10.1093/annonc/mds124